Abstract | OBJECTIVE: CASE SUMMARY: DISCUSSION:
Atorvastatin and colchicine have well-known myotoxic adverse effects. Despite atorvastatin's proven safety, its use with certain drugs, such as colchicine, makes it a potential myotoxic drug. This might be because concomitant administration of P-glycoprotein substrates, such as statins, and colchicine, which is a P-glycoprotein inhibitor, modifies pharmacokinetics by increasing bioavailability and organ uptake of the substrates, leading to more adverse reactions and toxicities. CONCLUSIONS: We recommend checking the creatine kinase level one week after prescribing 2 or more potentially myotoxic drugs concomitantly, after dose increase of a myotoxic drug, or after prescribing a new drug to a patient already using other myotoxic agents.
|
Authors | Abdurrahman Tufan, Didem Sener Dede, Safak Cavus, Neriman Defne Altintas, Alper Bektas Iskit, Arzu Topeli |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
2006 Jul-Aug
Vol. 40
Issue 7-8
Pg. 1466-9
ISSN: 1060-0280 [Print] United States |
PMID | 16772404
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
- Anticholesteremic Agents
- Heptanoic Acids
- Pyrroles
- Atorvastatin
- Creatine Kinase
- Colchicine
|
Topics |
- ATP Binding Cassette Transporter, Subfamily B, Member 1
(antagonists & inhibitors, metabolism)
- Adult
- Anticholesteremic Agents
(adverse effects)
- Atorvastatin
- Colchicine
(adverse effects)
- Creatine Kinase
(blood)
- Drug Interactions
- Heptanoic Acids
(adverse effects)
- Humans
- Male
- Pyrroles
(adverse effects)
- Rhabdomyolysis
(blood, chemically induced)
|